Guardant Health (GH) Fundamentals 2026 — Revenue Analysis | SniperIQ
Guardant Health (GH) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Guardant Health's market cap?
Guardant Health (GH) has a market capitalization of approximately
How profitable is Guardant Health?
Guardant Health runs a net profit margin of -40.1%, a gross margin of 64.9%, and an operating margin of -41.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Guardant Health generate?
Guardant Health reported revenue of $982M for fiscal year 2025, with net income of -$416M and earnings per share (EPS) of -3.32. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Guardant Health pay a dividend?
Guardant Health does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Guardant Health financially healthy?
Guardant Health carries a debt-to-equity ratio of -9.41x and a current ratio of 4.68x, with a market beta of 1.59. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Guardant Health a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Guardant Health (GH) the key facts are: market cap
Track Guardant Health's full fundamentals live
Get Guardant Health's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.